Alumis (NASDAQ:ALMS) Insider David Goldstein Sells 2,596 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) insider David Goldstein sold 2,596 shares of Alumis stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the completion of the sale, the insider owned 30,970 shares in the company, valued at approximately $816,678.90. This trade represents a 7.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $27.12 on Thursday. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35. The stock has a market capitalization of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69. The company’s 50-day moving average is $25.37 and its 200 day moving average is $25.22.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. Research analysts anticipate that Alumis Inc. will post -2.87 earnings per share for the current year.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

Wall Street Analyst Weigh In

Several research firms recently commented on ALMS. Guggenheim boosted their price objective on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Chardan Capital upped their price target on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Citigroup reiterated a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Finally, HC Wainwright reissued a “neutral” rating and issued a $25.00 target price on shares of Alumis in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alumis has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after acquiring an additional 4,926 shares during the period. Goldman Sachs Group Inc. lifted its position in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after buying an additional 11,949 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Alumis in the 1st quarter worth about $111,000. Rhumbline Advisers grew its holdings in Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Alumis by 163.2% in the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock worth $3,504,000 after purchasing an additional 724,133 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.